Guide
21 CFR 514 NADA & ANADA: A Practical Readiness Guide for FDA-CVM Submissions
21 CFR Part 514 governs the New Animal Drug Application (NADA) and Abbreviated NADA (ANADA) — the pathway through which FDA Center for Veterinary Medicine approves animal drugs for marketing in the United States. The submission sits over 21 CFR 211 cGMP, 21 CFR 511 INAD (investigational), 21 CFR 510.300 (medicated feed assay) and the CVM Guidance for Industry series. The 2023–2026 CVM modernisation has tightened pre-submission expectations, electronic submission gateway requirements (eSubmitter/CDER NextGen), and post-approval Annual Drug Experience Reports. This guide walks the integrated 514 framework, the recurring deficiency findings, and a practical path to a defensible NADA/ANADA submission and lifecycle.
Start free trial Free trial, no credit card, onboard in days, not months.
NADA vs ANADA vs INAD — pathway selection
NADA (514.1) is the full pathway — pioneer product with chemistry, manufacturing, controls (CMC), safety, effectiveness, target animal safety, human food safety (food species), and environmental impact. ANADA (514.91) is the generic pathway — bioequivalence to a reference listed drug. INAD (511) is the investigational pathway — pre-submission research authorisation. The 2023 CVM guidance refresh emphasised the pre-submission conference for NADA — entering the formal submission without the pre-submission alignment is now a recurring deficiency root cause.
The technical sections and the recurring CMC deficiencies
514.1(b) sets the technical sections — chemistry and manufacturing controls (drug substance and drug product), safety, effectiveness, target animal safety, human food safety for food species, environmental, labelling. CMC deficiencies dominate the post-2023 deficiency letter analysis — process validation evidence, container closure integrity for the labelled storage horizon, and stability data with the right number of batches and the right pulls. The deficiency is rarely the absence of data — it is data the sponsor did not link explicitly to the label claim.
Target animal safety and human food safety — the food-species overlay
Target animal safety (TAS) studies establish the safety margin in the labelled species at the labelled dose, with the safety multiple required by CVM guidance. Human food safety (HFS) for food-producing species requires the total residue study, the marker residue, the tolerance, and the withdrawal time validated against an approved analytical method. The 2024 CVM guidance refresh on residue depletion studies tightened the analytical method validation expectations. A food-species NADA with thin HFS evidence will not approve regardless of how strong the TAS data are.
Post-approval lifecycle: supplements, ADERs and the Annual Report
Post-approval, 514.8 governs supplements (manufacturing changes — Type II prior-approval, Type III CBE-30/CBE-0, annual reportable) and 514.80 governs adverse drug experience reporting on Form 1932 with the 15-day expedited window for serious unexpected events. The Annual Drug Experience Report (ADER) is due each year on the anniversary of approval. Recurring finding: supplements filed at the wrong Type level, or ADER tables that don't reconcile against the Form 1932 submissions for the year.
A 90-day pre-submission readiness path
Days 1–15: pathway selection (NADA/ANADA/INAD) and pre-submission conference scheduling. Days 16–35: technical section gap analysis with explicit label-claim linkage. Days 36–55: CMC validation refresh — process, container closure, stability. Days 56–75: TAS/HFS evidence refresh against current CVM guidance. Days 76–85: electronic submission gateway dry-run. Days 86–90: pre-submission conference and submission readiness rehearsal.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Is the pre-submission conference required?
Not strictly mandatory but practically essential since 2023. The CVM review division uses the conference to align on study design, data adequacy and submission scope. Submissions that skip the conference frequently receive deficiency letters on issues the conference would have caught.
What is the difference between a Type II and Type III supplement?
Type II is prior-approval — the change cannot be implemented until CVM approves the supplement. Type III is CBE (Changes Being Effected) — CBE-30 implements 30 days after submission absent CVM objection; CBE-0 implements immediately. Routing depends on the change's impact on identity, strength, quality, purity or potency.
Does an ANADA need its own TAS and HFS studies?
Generally no — the ANADA references the pioneer product's TAS and HFS via demonstrated bioequivalence. The bioequivalence study itself plus any product-specific safety considerations remain the sponsor's burden. Some food-species ANADAs do require confirmatory residue depletion under current CVM guidance.
When is Form 1932 'expedited' (15-day) vs 'periodic' (ADER)?
Form 1932 with 15-day expedited reporting applies to serious unexpected adverse drug experiences. All other adverse drug experiences are captured in the Annual Drug Experience Report tables. Mis-classification — particularly under-reporting of unexpected events — is a recurring inspection finding.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
Spot something off? .